Piper Sandler Maintains Overweight on Gilead Sciences, Lowers Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Gilead Sciences (NASDAQ:GILD) but lowered the price target from $105 to $100.
July 24, 2023 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Gilead Sciences but lowered the price target from $105 to $100.
The news is directly about Gilead Sciences and is likely to impact its stock. While the Overweight rating is positive, the lowering of the price target may have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100